Kalet León

1.5k total citations
59 papers, 887 citations indexed

About

Kalet León is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Kalet León has authored 59 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Immunology, 18 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Kalet León's work include T-cell and B-cell Immunology (27 papers), Immune Cell Function and Interaction (22 papers) and Immunotherapy and Immune Responses (17 papers). Kalet León is often cited by papers focused on T-cell and B-cell Immunology (27 papers), Immune Cell Function and Interaction (22 papers) and Immunotherapy and Immune Responses (17 papers). Kalet León collaborates with scholars based in Cuba, Portugal and United States. Kalet León's co-authors include Jorge Carneiro, Agustín Lage, José Faro, Tania Carmenate, Ernesto Moreno, Michel Enamorado, Rolando Pérez, Jorge Fernández-de-Cossio-Díaz, Tiago Paixão and Roberto Mulet and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Kalet León

54 papers receiving 861 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kalet León Cuba 19 526 256 242 137 72 59 887
Antonio Cappuccio France 14 623 1.2× 340 1.3× 240 1.0× 54 0.4× 39 0.5× 24 1.1k
Marian L. Turner Australia 11 720 1.4× 401 1.6× 130 0.5× 66 0.5× 27 0.4× 12 1.0k
Idan Milo Israel 11 638 1.2× 360 1.4× 380 1.6× 25 0.2× 79 1.1× 13 1.1k
Sri Krishna United States 13 393 0.7× 474 1.9× 388 1.6× 84 0.6× 40 0.6× 36 1.0k
Hashem Koohy United Kingdom 16 598 1.1× 765 3.0× 310 1.3× 105 0.8× 41 0.6× 30 1.5k
Mario Novković Switzerland 18 591 1.1× 459 1.8× 268 1.1× 14 0.1× 51 0.7× 24 1.1k
Grigory A. Efimov Russia 15 271 0.5× 186 0.7× 113 0.5× 97 0.7× 21 0.3× 46 555
Cédric R. Weber Switzerland 15 439 0.8× 629 2.5× 124 0.5× 446 3.3× 35 0.5× 21 953
Cris Kamperschroer United States 13 502 1.0× 104 0.4× 277 1.1× 118 0.9× 22 0.3× 26 738
David Requena United States 16 427 0.8× 397 1.6× 623 2.6× 58 0.4× 49 0.7× 35 1.3k

Countries citing papers authored by Kalet León

Since Specialization
Citations

This map shows the geographic impact of Kalet León's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kalet León with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kalet León more than expected).

Fields of papers citing papers by Kalet León

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kalet León. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kalet León. The network helps show where Kalet León may publish in the future.

Co-authorship network of co-authors of Kalet León

This figure shows the co-authorship network connecting the top 25 collaborators of Kalet León. A scholar is included among the top collaborators of Kalet León based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kalet León. Kalet León is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
León, Kalet, et al.. (2023). NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s.. Alzheimer s & Dementia. 19(S21).
2.
Figueredo, Carlos Marcelo, Mayra Ramos, Danay Saavedra, et al.. (2021). An Anti-CD6 Antibody for the Treatment of COVID-19 Patients with Cytokine-Release Syndrome: Report of Three Cases. Immunotherapy. 13(4). 289–295. 8 indexed citations
3.
Crombet, Tania, et al.. (2021). Reposicionamiento del anticuerpo monoclonal humanizado anti-CD6 itolizumab en el tratamiento de pacientes con COVID-19. SHILAP Revista de lepidopterología.
4.
Fernández-de-Cossio-Díaz, Jorge, et al.. (2021). In‐silico media optimization for continuous cultures using genome scale metabolic networks: The case of CHO‐K1. Biotechnology and Bioengineering. 118(5). 1884–1897. 16 indexed citations
5.
Dy, Grace K., et al.. (2021). The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology. 11. 639745–639745. 10 indexed citations
6.
Deligne, Claire, et al.. (2020). A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy. OncoImmunology. 9(1). 1770565–1770565. 2 indexed citations
7.
Montijano, J.I., et al.. (2020). Efficacy of direct current generated by multiple-electrode arrays on F3II mammary carcinoma: experiment and mathematical modeling. Journal of Translational Medicine. 18(1). 190–190. 6 indexed citations
8.
Ramos, Mayra, Danay Saavedra, Zaima Mazorra, et al.. (2020). Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19. Gerontology. 66(6). 553–561. 22 indexed citations
9.
Basto, Afonso P., S. C. P. Almeida, Carine M. Gonçalves, et al.. (2019). Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 47. 427–435. 11 indexed citations
10.
Carmenate, Tania, et al.. (2018). Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells. The Journal of Immunology. 200(10). 3475–3484. 40 indexed citations
11.
Dy, Grace K., Marvin Reid, Kwanghyuk Lee, et al.. (2018). P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S740–S740. 2 indexed citations
12.
Fernández-de-Cossio-Díaz, Jorge, Kalet León, & Roberto Mulet. (2017). Characterizing steady states of genome-scale metabolic networks in continuous cell cultures. PLoS Computational Biology. 13(11). e1005835–e1005835. 19 indexed citations
13.
Blanco, Rancés, et al.. (2016). Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it’s potential therapeutic implications. Clinical & Experimental Metastasis. 33(7). 717–725. 15 indexed citations
14.
León, Kalet, et al.. (2013). Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics. Frontiers in Immunology. 4. 439–439. 11 indexed citations
15.
Díaz, Yanelys Morera, et al.. (2012). Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response. Cancer Immunology Immunotherapy. 62(3). 455–469. 10 indexed citations
16.
Hymery, Nolwenn, et al.. (2009). T-2 toxin inhibits the differentiation of human monocytes into dendritic cells and macrophages. Toxicology in Vitro. 23(3). 509–519. 30 indexed citations
17.
León, Kalet, et al.. (2007). How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies. The Journal of Immunology. 179(9). 5659–5668. 20 indexed citations
18.
León, Kalet, José Faro, & Jorge Carneiro. (2004). A general mathematical framework to model generation structure in a population of asynchronously dividing cells. Journal of Theoretical Biology. 229(4). 455–476. 50 indexed citations
19.
León, Kalet, Rolando Pérez, Agustín Lage, & Jorge Carneiro. (2001). Three-Cell Interactions in T Cell-Mediated Suppression? A Mathematical Analysis of Its Quantitative Implications. The Journal of Immunology. 166(9). 5356–5365. 17 indexed citations
20.
León, Kalet, Rolando Pérez, Agustín Lage, & Jorge Carneiro. (2000). Modelling T-cell-Mediated Suppression Dependent on Interactions in Multicellular Conjugates. Journal of Theoretical Biology. 207(2). 231–254. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Cappuccio Breakdown of academic impact, for papers by Marian L. Turner Breakdown of academic impact, for papers by Idan Milo Breakdown of academic impact, for papers by Sri Krishna Breakdown of academic impact, for papers by Hashem Koohy Breakdown of academic impact, for papers by Mario Novković Breakdown of academic impact, for papers by Grigory A. Efimov Breakdown of academic impact, for papers by Cédric R. Weber Breakdown of academic impact, for papers by Cris Kamperschroer Breakdown of academic impact, for papers by David Requena
Rankless by CCL
2026